FDA Expands ASCENIV Pediatric Use - Takeaways - MDSpire
FDA & Government News

FDA Expands ASCENIV Pediatric Use

Label change follows completion of required pediatric evaluation and updates prior age restrictions for treatment eligibility.

  • By

  • Kathryn Wighton

  • May 4, 2026

  • 2 min

Share

  • 1

    ASCENIV is now approved for pediatric patients aged 2 and older.

  • 2

    It treats primary humoral immunodeficiency.

  • 3

    The approval followed a pediatric assessment study.

  • 4

    Risks include thrombosis and renal dysfunction.

  • 5

    Common adverse events involve respiratory infections and gastrointestinal issues.

  • 6

    ASCENIV utilizes a unique plasma donor screening method.

  • 7

    Initial approval was in April

  • 8

    Patient monitoring is essential during treatment.

Original Source(s)

FDA Expands ASCENIV Pediatric Use

  • by Kathryn Wighton

  • May 4, 2026

Related Content

Smartwatch May Track AD Status in Children

Wearable-derived scratching measures align with disease activity and short-term treatment response in pediatric patients with atopic dermatitis.

AAP Updates Pediatric Office Emergency Readiness

Guidance addresses office readiness, recommended equipment and medications, and team communication processes for infrequent but high-acuity emergencies.

FDA Reports Results of Nationwide Infant Formula Testing

Federal testing survey examines chemical contaminant profiles across widely used products